Photocure ASA (0IMT) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Photocure Asa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:02.034 All right, well, good afternoon and good morning. 00:00:02.034 -- 00:00:06.602 This is Dan Schneider, CEO and President of Photocare. 00:00:06.602 -- 00:00:13.289 With me today is Eric Dahl, CFO, and welcome to the first quarter 2025 results. 00:00:13.593 -- 00:00:19.239 Just a reminder, the usual disclaimers are in place for today's presentation. 00:00:19.640 -- 00:00:23.344 So let's just first start with our strategic priorities and initiatives to make sure 00:00:23.344 -- 00:00:25.406 everyone's well grounded. 00:00:25.406 -- 00:00:29.710 We plan on delivering on our financial guidance for growth and revenue and EBITDA this 00:00:29.710 -- 00:00:32.493 year and continue generating operating income. 00:00:32.493 -- 00:00:36.837 We are driving the mobile strategy. We'll get into that today and its success so far, 00:00:36.837 -- 00:00:40.781 and also increasing our penetration, our priority growth markets, and we have some recent 00:00:40.781 -- 00:00:45.686 developments to talk about there as well, and to continue to expand our geographic footprint 00:00:45.686 -- 00:00:48.175 and leverage our distribution partnerships. 00:00:48.175 -- 00:00:52.782 In positioning and access, it's really key here that we don't become the next Kodak film. 00:00:52.782 -- 00:00:58.331 And by that, I mean we need to remain relevant in the marketplace and strengthen 00:00:58.331 -- 00:01:03.500 our position as the primary diagnostic for precision diagnostics in bladder cancer 00:01:03.500 -- 00:01:08.508 care as we see the new emerging non-muscle invasive bladder cancer therapies 00:01:08.508 -- 00:01:13.525 come to market. In addition, we want to support the continued entrance 00:01:13.525 -- 00:01:16.132 of high-def blue light machines into the U.S....